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DEBORAH E. HARTMANN 
The standard therapy for preventing copper accumu- 
lation in Wilson’s disease, n-penicillamine, has been a 
life-saving drug, but it has many side effects and some 
patients are completely intolerant. We have been using 
oral zinc as another approach to the therapy for Wilson’s 
disease, with copper balance studies as the key initial 
assessment of the adequacy of a given dose or regimen 
of zinc therapy. We earlier reported that an intensive 
regimen of zinc (zinc taken every 4 hr) was effective in 
controlling copper balance. We have now shown with 
balance studies that a simplified zinc therapy regimen 
of 60 mg zinc taken 3 times per day is effective in 
controlling copper balance. Preliminary work presented 
here with other simplified regimens also indicate their 
effectiveness. These studies increase the data base, in 
terms of copper balance, for zinc therapy of Wilson’s 
disease, and expand the dose range and regimens of zinc 
which have been shown to control copper balance. 
Wilson’s disease is an autosomal recessive disease of 
copper accumulation, with copper toxicity manifesting 
primarily in the liver and/or brain. The disease is pro- 
gressive and ultimately fatal if untreated. The search for 
substances to remove copper brought forth the use of 
penicillamine in 1956 by Walshe (l) ,  and many lives 
have been saved by this type of chelation therapy. How- 
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ever, an appreciable percentage of Wilson’s disease pa- 
tients have an initial hypersensitivity reaction to peni- 
cillamine (2), and some have sufficient side effects that 
life long therapy with penicillamine becomes difficult or 
impossible (3). Recently, Trien, which acts by chelation 
and urinary excretion of copper as does D-pencillamine, 
has been approved by the Food and Drug Administration. 
Much less is known about the long-term toxicity of this 
drug than with either penicillamine or zinc. 
Zinc, a known antagonist of copper, has been intro- 
duced as an alternative therapy for Wilson’s disease. As 
early as 1946 (4), zinc had been shown to produce copper 
deficiency in experimental animals. In 1977, we observed 
(5) that sickle cell anemia patients being treated with 
zinc developed copper deficiency. As a follow-up, we 
began trials using zinc as a therapeutic agent for the 
treatment of Wilson’s disease (6). 
Meanwhile, a group in Holland published the first 
paper on zinc treatment of Wilson’s disease (7), present- 
ing primarily clinical evidence of efficacy without balance 
studies. This group also cited earlier work in an unpub- 
lished thesis by Schouwink (Academisch Proetschrift 
Amesterdam, Van der Wiel, Arnhem, 1961, Utrecht, 
Holland) reporting negative copper balance in two pa- 
tients while on zinc therapy. The Holland group has 
published additional clinical follow-up studies showing 
zinc efficacy from the clinical standpoint (8) and have 
employed %opper uptake to evaluate zinc therapy (9). 
In our work, copper balance has been the cornerstone 
measure for initial indication of adequacy of a given dose 
of zinc in each patient. Our original zinc therapy regimen 
was intensive and tedious. It involved taking zinc 5 or 6 
times per day, avoiding food by an hour with each dose. 
Thus, the objectives of the work presented herein were 
to determine if smaller doses of zinc and less tedious 
regimens would be effective in controlling copper balance 
in Wilson’s disease patients. 
MATERIALS AND METHODS 
Included in this study were 14 
adult Wilson’s disease patients who had the clinical and bio- 
chemical features of Wilson’s disease, partially summarized in 
Table 1, and who were mentally capable of giving informed 
Patients and Subjects. 
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TABLE 1. Characteristics of Datient WDPlation 
Our Bilirubin' AST' WBC' Phbl&' 
patient sex Age Clinical sequelae (mg/dl) (IU/Uter) (1 ,OOO/cma) ( 1.000/cm8) 
1 M 34 Cirrhosis-bilirubin (5.5-5.1) 2.9 34 4.9 49 
3 M 35 Dysarthria 0.7 13 4.6 122 
no. (yr) (Normal = 0 . 1 4 . 9 )  (Normal = 2-35) (Normal = 4-10) (Normal = 200-400) 
2 M 22 Dysarthria 0.4 28 4.0 123 
4 F 32 Neurologic-dysarthria, dystonia of face 0.3 25 6.2 177 
and extremities 
5 F 33 Neurologic-dysarthria, dystonia of face 0.3 
and extremities 
18 5.6 191 
6 F 35 Neurologic-dysarthria. dystonia of face 0.4 31 5.2 186 
7 F 38 Neurologic-dysarthria. dystonia of face 0.5 21 4.6 160 
9 F 48 Mild dysarthria 0.5 27 8.7 196 
and extremities 
and extremities 
10 F 26 Normal 0.5 28 7.8 214 
11 F 26 Neurologic-dysarthria, mild dystonia of 0.6 16 4.6 244 
12 F 25 Neurologic-dysarthria, mild dystonia 0.4 20 7.1 132 
17 F 27 Neurologic-dysarthria, dystonia of face 0.8 21 4.2 177 
24 M 19 Neurologic-mild dysarthria, tremor 0.4 21 6.5 249 
0.4 21 8.3 158 36 M 32 Depression, easy fatigability 
face and right arm 
on right 
and extremities 
~~~~ ~ _ _  . - 
~~ 
Study Urine copper N o n ~ r u l o p l ~ ~ ~ i ~  
Start End Start End 
( r d 2 4  hr)' plasma copper (rddl) 
- interval 
Our Ceruloplasmin' 
no. (Normal = 25-35) dry weight) (Months) 
Liverb copper patient (mg/dl) 
~ 1 2.3 18 60 55 8 12 
2 2.5 - 
3 5.0 183 12 51 53 11 <1 
4 6.9 - 13 80 60 14 11 
5 5.1 678 18 101 50 24 22 
6 4.3 134 18 51 51 38 16 
7 3.7 253 15 55 43 20 18 
9 11.6 162 15 53 32 7 14 
- 22 - 1 80 
- 15 
10 
- 10 13.2 316 1 10 
11 1.8 112 1 51 
12 4.0 106 12 53 60 27 12 
17 12.0 358 18 92 84 16 18 
24 1 .o 510 1 57 






These values are the average of several determinations in each case. 
Values at  the time our studies began. 
' Values presented are the mean of three 24-hr determinations using an IL 451 AA, which is quite reliable in this range. Normal values are 45 
pg/24 hr or lower. Typical values for untreated or only partially decoppered Wilson's disease patients are 150 pg/24 hr or higher. 
consent or consent was given by their legal guardian. Thirteen 
of the patients had been on penicillamine therapy for several 
years and were in stable clinical condition. These patients had 
good evidence of adequate decoppering, as manifested, for ex- 
ample, by relatively low liver copper on biopsy, the continual 
absence of Kayser-Fleischer rings, low urinary copper excretion 
in the absence of penicillamine and low nonceruloplasmin 
plasma copper (a measure of readily available copper). The 
fourteenth patient (No. 36 of Table 1 ) had been newly diag- 
nosed and had not been treated with anticopper medication. 
Eleven of the patients had presented with neurological symp- 
toms and carried residual neurological sequelae (Table 1). One 
patient (No. 36) had presented with behavioral abnormalities, 
one (No. 10) had been diagnosed while clinically normal and 
one (No. 1) had presented with frank liver disease. While only 
this patient had liver disease a t  the clinically detectable level, 
10 other patients had evidence of subclinical cirrhosis and 
hypersplemism as manifested by thrombocytopenia (Table 1). 
Many of these patients also had a tendency toward leukopenia 
(Table 1 ) .  Serum enzymes derived from the liver were in the 
normal range, as exemplified by AST levels (Table 1). 
Normal volunteers known to be in good health and in the 
age range of the Wilson's disease patients were participants in 
the perspiration study. This research was performed according 
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to the Declaration of Helsinki, informed consent was obtained 
in all cases and the University of Michigan Human Experimen- 
tation Committee approved these studies. 
Our first objective in this work was to 
document that a particular simplified regimen of zinc therapy 
(we selected 50 mg given three times per day for reasons 
elaborated on in the "Discussion") would adequately control 
copper balance in Wilson's disease patients. A second objective 
was to compare copper balance in Wilson's disease patients on 
various other simplified regimens of zinc therapy. With respect 
to this latter objective, ideally one would like to study each 
patient on each regimen, thus allowing direct comparison of 
the effectiveness of each regimen on the identical group of 
patients. However, certain practical limitations, such as rarity 
of the disease, the amount of time required of each patient per 
balance (14 days) and the large costs involved in the hospital 
admissions, prevented the attainment of that ideal. Because of 
these limitations, the number of patients studied with the 
various regimens other than 50 mg 3 times per day (10 patients 
a t  this dose) was 3 or 4 each. Three patients volunteered for 
four studies, five patients for two studies and the remainder 
was studied only once. An equilibration period of a t  least 3 
months was allowed on each new dose to be studied in patients 
who were studied more than once. Normally, 1 to 3 weeks of 
zinc therapy is adequate to produce a maximal therapeutic 
effect (6). 
Zinc Therapy Regimens. The zinc therapy regimens 
used for this study were: 25 or 50 mg zinc 3 times per day, given 
at  0700,1500 and 2300 hr; 50 mg zinc 2 times per day, given a t  
lo00 and 2200 hrs and 25 mg zinc 4 times per day, given a t  
0700,1100,1600 and 2100 hr. All medication schedules for zinc 
administration avoided food and beverages for 1 hr before and 
after zinc ingestion. This is necessary because many foods have 
substances which chelate or bind zinc and prevent its effective- 
ness (10, 11). Elemental zinc was supplied as zinc acetate in 
tablets except for Patient 6, for whom zinc sulfate capsules 
were used per her request. Zinc acetate is used because without 
concomitant food ingestion, it has been our experience that 
zinc sulfate can be irritating to the stomach, while the acetate 
salt is well-tolerated. All medications were assayed in our 
laboratory to guarantee accuracy of zinc dose. 
All patients stopped their previous an- 
ticopper therapy and began taking zinc on the regimen to be 
studied a t  least 3 months prior to admission to the Clinical 
Research Center at the University of Michigan. No food or 
beverage (except deionized-distilled water) was to be consumed 
for 1 hr before or after taking each dose of the zinc. Foods and 
beverages to be consumed daily were selected by the patient, 
purchased prior to admission in sufficient quantity for the 
entire balance period and were prepared in the metabolic 
kitchen a t  the Clinical Research Center. Thus, the same foods 
and beverages were consumed each day during the balance 
period to guarantee constant copper intake. Diet selection by 
the patient was to reflect as closely as possible the diet con- 
sumed in their daily life and not necessarily a "well-balanced" 
diet. However, sufficient calories and protein were consumed 
to maintain body weight during the balance period. Food was 
prepared in stainless steel vessels and served on or in paper 
containers shown not to contribute copper or zinc to the foods. 
Duplicate daily food and beverage composites, identical to that 
consumed by the patient, were prepared twice during each 
balance period for copper and zinc analysis. 
Fecal excretion during the balance period was delineated by 
50 mg U.S. food color FDC#l at 0700 on the first and last days 
of the constant diet. All balance periods were a minimum of 10 
days in duration. All stools were collected in preweighed poly- 
propylene containers and stored a t  4°C until preparation for 
Study Design. 
Copper Balance. 
analysis. Twenty-four hour urine samples were collected in acid 
washed containers, measured, aliquoted into 250 ml polyethyl- 
ene containers and frozen at -20°C until analyzed for zinc and 
copper. Plasma was drawn into trace element-free syringes and 
anticoagulated with heparin which had passed through a chelex 
100 column to remove zinc and copper. After centrifugation, 
plasma was frozen at -20°C. 
Forearm Perspiration Collection for Copper Analy- 
sis. One forearm, including the hand of the patient or subject 
to be studied, was scrubbed with soap and rinsed 3 times with 
deionized-distilled water, and then wrapped with a plastic food 
wrap bag shown to be free of copper. The patient or subject sat 
in a sauna a t  a temperature of 93°F for 30 min and the 
perspiration from the arm collected in the bottom of the plastic 
bag. The perspiration was transferred to a plastic tube and the 
copper concentration determined. 
Homogenized food composites and stool Sam- 
ples were weighed, lyophilized, reweighed and digested with 
redistilled nitric acid (Baker Instra-Analyzed, J. T. Baker 
Chemical Co., Phillipsburg, NJ) until digestion was complete. 
Appropriately diluted plasma, digested food and fecal samples, 
and undiluted urine and perspiration were analyzed for copper 
and zinc concentration by atomic absorption spectrophotome- 
try on an IL451 (Instrumentation Laboratory, Inc., Wilming- 
ton, Mass.) or a Perkin-Elmer 306 (Perkin-Elmer, Norwalk, 
Conn.). In all cases, the appropriate standards were used with 
the sample. 
Apparent copper 
balance is defined as copper intake (food) minus copper ex- 
creted (fecal plus urine). In this study, we classified each 
balance result into 1 of 3 categories, which are as follows: (i) 
positive balance-greater than +0.25 mg positive balance per 
day; ( i i )  negative balance-a more negative balance than -0.15 
mg per day, and (iii) neutral balance-between +0.25 mg and 
-0.15 mg per day. The average loss of 0.34 mg copper per day 
from the skin's surface has been reported in normal subjects 
(12). Although the surface loss of copper in Wilson's disease 
has not been measured quantitatively, our preliminary data 
(presented in the "Results" section) indicate similar losses in 
perspiration of normal and Wilson's disease patients. Since 
surface losses were not considered in the balance data presented 
herein, an apparent positive balance of +0.25 mg per day would 
result in an actual negative balance averaging -0.09 mg. Since 
the daily intake of copper is about 1.0 mg per day, an apparent 
balance of +0.25 mg would have to be in error by 0.09 mg, or 
almost 10% of the total intake, before even a slight positive 
balance would go undetected. A loss of copper greater than 0.15 
mg per day represents an appreciable loss of copper and seems 
a reasonable point below which to define a balance as definitely 
negative. 
Student's t test (13) was utilized to 
compare the copper concentration in forearm perspiration of 
Wilson's disease patients and controls, and to compare the 
mean copper balance of patients taking 150 mg zinc per day 
with the copper balance in patients taking a smaller dose of 
zinc. Linear regression (13) of copper balance data on the total 
zinc dose was also performed. 
Analyses. 
Interpretation of  Copper Balance. 
Statistical Methods. 
RESULTS 
Concentrations of Copper in Perspiration. Data 
on copper concentration in forearm perspiration (Table 
2) indicate that Wilson's disease patients lose at  least as 
much copper in perspiration as normal subjects. 
Copper Balance on 50 mg Zinc 3 Times Per 
Day. Results of studies in 10 patients on this regimen 
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TABLE 2. Copper concentration in forearm perspiration of 
Wilson's disease patients and controls. 
TABLE 3. Average daily copper balance of Wilson's disease 
patients on 50 mg zinc 3 times per day 
disease Copper concentration concentration Copper 




Patient Copper (mg/day) 
Diet Fecal Urinary Balance no. 
1 133.8 1 21.9 
3 8.1 - 24.6 
5 18.6 3 61.7 
7 222.6 4 52.3 




Mean = 71.3 f 79.3 ( + I  S.D.) 37.0 ? 18.6 
p = nonsignificant (I test) 
This study was performed by collecting perspiration from the 
forearm by placing the scrubbed hand and forearm in a trace element- 
free plastic bag, sealed around the arm with elastic and having the 












1.06 0.94 0.05 
0.66 1.13 0.08 
1.43 1.57 0.10 
0.72 0.65 ND" 
1.20 1.25 0.09 
0.52 0.63 0.03 
0.77 1.47 0.01 
0.M 1.16 0.05 
1.20 1.45 0.09 











Mean 1.003 1.18 0.056 -0.23 
a ND = not detectable with flame atomic absorption spectrophotom- 
etry (Perkin-Elmer). 
(Table 3) show that a negative or a neutral copper 
balance was achieved in all 10 individuals, with an overall 
mean negative balance of -0.23 k 0.26 mg copper per 
day- 
Copper Balance on 50 mg Zinc 2 Times Per 
Day. Negative or neutral balances were achieved in all 
three patients on this regimen, with a mean of -0.18 k 
0.40 mg copper per day (Table 4). 
Copper Balance on 25 mg Zinc 4 Times Per 
Day. Negative or neutral copper balance resulted for 
all four patients on this regimen, with a mean of -0.23 
k 0.17 mg copper per day (Table 5). 
Copmr Balance on 25 mg Zinc 3 Times Per 
Day. Negative or neutral copper balance resulted with 
this regimen in all three patients, with a mean of -0.13 
k 0.07 mg copper per day (Table 6). 
Eleven of the 20 copper balances performed with var- 
ious zinc treatment regimens were classified as a negative 
copper balance, and 9 were classified as neutral. Only 
four balances had slightly positive apparent balances of 
0.03, 0.07, 0.07 and 0.16 mg per day, and these were 
classified as neutral because of assumed skin surface 
losses, as previously discussed. Overall, the observed 
copper balance averaged -0.20 mg per day. In contrast, 
in three Wilson's patients not on anticopper therapy, we 
have obtained blance results of +O.'iS, +0.54 and +0.69, 
averaging +0.66 mg copper per day (Patients 2 , 3  and 36 
of the first column in Table 7, and diamond symbols in 
Figure 1). The means of the balance data vs. daily dose 
of zinc are also illustrated in Figure 1, which includes 
data on 25 mg 6 times per day from a previous paper 
(Square symbol) (6). Comparison of the mean copper 
balance of the 15 patients taking 150 mg zinc per day 
with the mean of the 10 patients taking a smaller dose 
(Figure 1) revealed no significant difference (t = 0.55, p 
= not statistically significant). Further, regression of 
copper balance on total zinc dose for these 25 balances 
did not reveal a significant effect. We conclude that, in 
this group of patients, all in a relatively "decoppered 
state, there was no evidence of a dose effect within the 
dose range studied. The main point is that all of the 
TABLE 4. Average daily copper balance of Wilson's diseaee 
patients on 50 mg zinc 2 times per day 
Copper (mg/day) 
Diet Fecal Urinary Balance 
~ ~~~ ~ ~ 
Patient 
no. 
1 1.09 1.73 ND" -0.64 
4 1.11 1.11 0.06 -0.06 
12 1.11 0.94 0.01 +0.16 
Mean 1.10 1.26 -0.18 
" ND = not detectable with flame atomic absorption spectrophotom- 
etry (Perkin-Elmer). 
TABLE 5. Average daily copper balance in Wilson's disease 
patients on 25 mg zinc 4 times per day 
1 1.27 1.47 0.03 -0.23 
:1 0.79 0.71 0.10 -0.02 
5 0.49 0.83 0.0" -0.36 
7 1.22 1.49 0.04 -0.31 
Mean 0.94 1.12 0.05 -0.23 
TABLE 6. Average daily copper balance of Wilson's dieeaee 
patients on 25 mg zinc 3 times per day 
1 1.42 1.39 0.06 -0.03 
4 0.76 0.92 0.03 -0.19 
17 0.89 0.97 0.08 -0.16 
Mean 1.02 1.09 0.m -0.13 
regimens produce satisfactory evidence of copper balance 
control. 
Daily dietary intake of copper in the 20 patient-se- 
lected diets ranged from 0.49 to 1.61 mg with an average 
of 1.01 mg (Tables 3 to 6). As expected, fecal copper loss 
was the main route of copper excretion, resulting from 
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TABLE 7. Copper balance data on Wilson’s disease patients on no treatment (Patients 2.3 and 36) and serial copper balance 
data on patients who have had more than one balance” (total dose of zinc in parentheses) 
Monthly intervals of subsequent studies alter first study Patient 
0 1-6 7-12 13-18 19-24 26-30 no. 
1 -0.42 (150)” -0.23 (100) -0.03 (75) -0.64 (loo) 
2 +0.75 (0 )  -0.44 (150)” 
3 +0.54 (0) -0.02 (150)’ -0.02 (loo) +0.07 (150) -0.13 (100) 
4 -0.16 (150)” -0.55 (150) -0.19 (75) -0.06 (loo) 
5 -0.03 (150)” -0.36 (100) -0.24 (150) 
6 +0.07 (150) -0.07 (150) 
I -0.14 (150) -0.31 (100) 
12 -0.35 (150) +0.16 (100) 
36 +0.69 (0 )  
17 -0.34 (150) -0.16 (75) 
Data are included from a previous paper (6) in which the daily dose 












1 1  I I I 
0 75 100 150 
DAILY ZINC DOSE (mg) 
FIG. 1. The mean copper balances on the four zinc regimens studied 
in this paper (circles) plus the mean copper balance data from a 
previously studied regimen ( sqwre )  (6) are plotted against daily intake 
of zinc. In addition, copper balance obtained from three patients while 
not on anticopper therapy are plotted (diamonds). The means and 
standard deviations for the various treatments shown on this figure are 
as follows: 25 mg 3X = -0.13 f 0.07; 25 mg 4X = -0.23 ? 0.17; 50 mg 
2x = -0.18 f 0.40; 50 mg 3X = -0.23 f 0.26; 25 mg 6X = -0.21 & 
0.21. 
zinc therapy and ranged from 0.63 mg per day for Patient 
9 (50 mg 3 times per day) to 1.73 mg per day for Patient 
1 (50 mg 2 times per day), and averaged 1.15 mg per day 
(all data pooled). 
Table 7 provides copper balance data on three Wilson’s 
disease patients on no therapy at  the time of balance 
(Patients 2 ,3  and 36, first column). Patients 2 and 3 had 
been previously extensively treated with penicillamine, 
while Patient 36 had not. Nonetheless, the three positive 
balances are quite similar. Table 7 also provides serial 
copper balance data in the same patients, with approxi- 
was 150 mg (25 mg, 6 times per day). 
*mate time intervals in months indicated. The total daily 
dose of zinc at the time of the balance is indicated in 
parentheses. As was the case with the entire body of 
data, there is no apparent dose response trend in individ- 
ual patients. Further, there is no evidence of “tolerance” 
to zinc, resulting in a lessening effect as patients are on 
the therapy for long periods of time. 
DISCUSSION 
Thirteen of the patients studied were relatively well 
“decoppered as evidenced by disappearance of Kayser- 
Fleischer rings, relatively low urinary copper excretion 
and low values for nonceruloplasmin plasma copper (Ta- 
ble 1). During this study while on only continuous zinc 
therapy, a decoppered state was maintained as shown by 
low urinary excretion of copper and low nonceruloplas- 
min plasma copper (Table 1). These previously “decop- 
pered patients were maintained in negative or neutral 
copper balance with all of the regimens which were 
studied. As previously defined, 11 of the balance studies 
were negative and 9 were neutral. Actual values show 
four small positive balances (+0.07, +0.07, +0.03 and 
+O. 16) which, when considering the probable losses of 
copper in insensitive perspiration, are defined as neutral. 
Thus, in all 20 studies, zinc maintained an adequate 
control of copper balance. This is illustrated dramatically 
by contrasting these results with those of three untreated 
patients (diamond symbols in Figure 1; mean positive 
balance of 0.66 mg). 
Previous estimates in the literature indicated that 
copper intakes of the general population were in the 
range of 2 to 5 mg per day (14), and the National 
Academy of Sciences, National Research Council set a 
safe and adequate intake level of 2 to 3 mg of copper per 
day for adults (15). However, more recent work has 
indicated that the earlier estimates are much too high 
and that the actual copper intake of most Americans is 
around 1.0 mg or less per day (16-18). We have confirmed 
that the intake of copper in self-selected diets of six 
normal subjects is about 1.0 mg per day (Hill, G. M. et 
al., Am. J. Clin. Nutr. 1982; 35:XXI, Abstract). Thus, 
the diets of our Wilson’s disease patients contained, on 
average, about the same amount of copper that Ameri- 
cans consume and were not abnormally low. Further, the 
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diet while in the hospital was selected by each patient to 
be similar to that being ingested at home. 
To document that one particular simplified regimen of 
zinc therapy would adequately control copper balance in 
Wilson’s disease patients, we selected 50 mg 3 times per 
day and performed 10 studies with this regimen. The 
data in.the 10 individual patients in Table 3 demonstrate 
adequate control in each case. Further, the mean effect 
on balance from this 150 mg daily dose is comparable to 
the mean effect of the 150 mg daily dose given by the 
more tedious 25 mg 6 times per day previously reported, 
as shown in Figure 1. Thus, we conclude on the basis of 
the data in Table 3 that 50 mg zinc taken 3 times per 
day is generally effective in controlling copper balance 
in Wilson’s disease. 
To develop preliminary data on other simplified regi- 
mens, including the effect of reduction of total daily zinc 
dose, the 10 studies in Tables 4 to 6 were performed. 
Again, they illustrate adequate individual control of cop- 
per balance with each regimen, even with doses as low 
as 75 mg zinc per day. However, because of the limited 
number of studies, the evidence of efficacy of these lower 
doses must be viewed as preliminary. Over the dose range 
studied, there is no evidence of dose response to zinc in 
terms of an effect on copper balance in these well “de- 
coppered patients. As shown in Table 7, there is no 
indication of a “tolerance” to zinc developing. 
Zinc has been shown to induce intestinal metallothi- 
onein (19) which binds zinc and copper in the intestine 
and prevents their serosal transfer (20). Intestinal cells 
are sloughed with about a 6-day turnover (21), and the 
metallothionein-bound copper and zinc are lost in the 
stool and are thus not absorbed. Adequate zinc status is 
probably necessary for metallothionein induction to oc- 
cur. To assure adequate zinc status before the copper 
balance studies, all patients were pretreated with the zinc 
regimen to be tested for 3 months prior to admission. 
Metallothionein in various tissues of the rat appears to 
have a half-life of at least 12 hr (22), indicating that large 
doses of zinc, twice daily, should theoretically be ade- 
quate to continually stimulate metallothionein produc- 
tion for blocking copper uptake. The results reported 
here support this theoretical consideration and indicate 
that a frequency of zinc administration as low as twice a 
day is effective, at least in the three patients studied 
(Table 4). In patients who have gastric intolerance of the 
50 mg dose, it appears that 25 mg zinc taken 3 or 4 times 
per day is effective, although we have less experience 
with this regimen (Tables 5 and 6). 
Fecal copper comes from: (i) unabsorbed dietary cop- 
per and (ii) copper of endogenous secretions which was 
not reabsorbed. In rat studies, complexed copper of bili- 
ary secretions appears to be less available for reabsorp- 
tion than copper in saliva, pancreatic juice, gastric juice 
and intestinal secretions (23). Salivary and gastric secre- 
tions in Wilson’s disease patients contain approximately 
0.45 and 1.0 mg copper per 24 hr, respectively (24). If the 
secretions of the intestines contain at least 0.2 mg copper 
per day, approximately 1.65 mg of copper is contained in 
the daily endogenous secretions of a Wilson’s disease 
patient. Thus, the negative copper balance produced by 
zinc therapy probably comes from at least partial block- 
ade of absorption of both dietary and endogenously se- 
creted copper, resulting in high fecal excretion of copper. 
In our clinic, 39 patients are now on maintenance 
therapy with zinc, 14 for over 2 years; in each case, initial 
copper balance has been employed to demonstrate ade- 
quacy of therapy. Subsequently, these patients are mon- 
itored by a variety of techniques, including ‘%opper 
utpake (25), liver biopsy, measurement of urine and 
plasma copper and thorough clinical follow-up. In each 
case, zinc has proven effective in preventing the reaccu- 
mulation of copper and the occurrence or reoccurrence 
of symptoms. To date, in 10 previously decoppered pa- 
tients with serial liver biopsies over the course of l to 3 
years, zinc therapy has been shown to prevent the reac- 
cumulation of hepatic copper (Brewer, G. J. et al., Clin. 
Res. 1985; 33:871A, Abstract). 
Our experience with zinc therapy has primarily been 
with patients previously treated for several years with 
penicillamine, and who are thus relatively well-decop- 
pered, as manifested for example, by a 24-hr urine copper 
when off penicillamine therapy of 200 pg or less, and a 
nonceruloplasmin plasma copper of 25 pg or less. Thus, 
at present, patients of this type who are intolerant of 
penicillamine are the major candidates for zinc therapy. 
The use of zinc as an initial decoppering agent is cur- 
rently under investigation. 
We conclude that decoppered Wilson’s disease patients 
can be kept in negative or neutral copper balance with a 
simplified regimen of zinc therapy. The regimen we 
currently use for most of our patients is 50 mg 3 times 
per day. Patients to be placed on zinc therapy should be 
carefully monitored by as many of the following proce- 
dures as possible: %opper uptake; liver biopsy; urine and 
plasma copper; copper balance if available, and of course 
by clinical observation. 
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